Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

This study tests a new drug that blocks a protein called MELK (which helps cancer cells divide and grow) in women with advanced or metastatic breast cancer, including triple-negative breast cancer (a particularly aggressive form with fewer treatment options). **You may be eligible if...** - You are a female 18 years of age or older - You have been diagnosed with locally advanced or metastatic breast cancer (cancer that has spread beyond the breast) - Your cancer has stopped responding to standard treatments or no standard treatment is available - Your cancer has been confirmed by biopsy **You may NOT be eligible if...** - You have not yet tried standard treatment options - You have certain serious heart, liver, or kidney conditions - You are pregnant or breastfeeding This study may open up new options particularly for triple-negative breast cancer patients, who often have the fewest treatment choices. Talk to your doctor to see if this trial is right for you.